Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide

"Phase 1: Given via IV at the following dose levels:~* Level 1: 70 mg/m2~* Level -1: 50 mg/m2~* Level 2: 90 mg/m2~* Level 3: 120 mg/m2~Phase II: Given via IV on Days 1 and 2 of each cycle at the maximum-tolerated dose level found in the Phase I portion of the study."

"Phase II~* Cycle 1: 300 mg via IV on Day 1 and 1000 mg via IV on Day 3~* Cycles 2 and 3: 1000 mg via IV on Day 1"

Phase II: AUC 5 via IV on Day 2 of each cycle

Phase II: 100 mg/m2 via IV on Days 1, 2, and 3 of each cycle

CT Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment

PET Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment

"For potential transplant candidates:~* Autologous STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee~* Allogeneic STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee"